• New Glycan-Based Diagnostic May Refine Cancer Detection and Treatment

    Oct 16 | Diagnostics World | A new diagnostic tool could soon help oncologists identify which tumors are most vulnerable to a class of immunotherapies that target cancer’s sugar-coated surface. Researchers at the UC Irvine School of Medicine have developed a companion diagnostic that measures glycan density in tumor tissue, which could redefine how solid tumors are detected, classified, and treated. More

  • GPT Model Could Serve as ‘Early Warning System’ of Disease Risk

    Oct 15 | Diagnostics World | An innovative GPT model trained on vast amounts of anonymized data from healthy volunteers in the UK Biobank has been shown to be impressively good at predicting an individual’s risk of developing over 1,200 diseases over the next decade. Since the model represents disease risks as rates, it can also quantify how quickly new cases occur within a population over time. More

  • A Look at Early Rheumatoid Arthritis Paves New Paths Forward

    Oct 14 | Diagnostics World | As people with rheumatoid arthritis (RA) well know, it is a “forever disease” with no single magic-bullet cure or guarantee that they will ever feel like they did before their diagnosis. But a better understanding of what’s happening biologically before the first swollen joint appears could reveal opportunities to markedly modify the course of RA and, ultimately, prevent it. More

  • AI-powered Digital Pathology Workflows Support Confident Cancer Diagnosis

    Oct 10 | Diagnostics World | There are more cases of cancer in the U.S. than ever before. Over 2 million new cases are expected to be diagnosed in 2025 alone, and cancer incidence is on the rise in 6 of the 10 most common cancers. Delivering speedy, accurate diagnoses and treatment for a growing pool of cancer patients is a daunting challenge for today’s clinicians. More

  • Beyond the Brain Scan: How Emerging Blood Tests Could Change the Way Neurodegenerative Diseases are Detected and Diagnosed Down the Road

    Oct 01 | Diagnostics World | We have entered a new era of science focused on developing tools and technologies to support early detection and diagnosis. The rapid evolution of research has led to the need to systematically collect, review, and distill findings into clear and actionable recommendations for how to use these tools in clinical practice More

  • ‘Super-Simple’ NLP Model Labels Origin of Metastatic Cancer

    Sep 30 | Diagnostics World | For patients with metastatic brain cancer, stereotactic radiosurgery has become an increasingly common treatment over the past decade based on the recommendations of medical physicists, guidelines of professional societies, and coverage guidelines of federal agencies. There has also been a change in the drugs used to treat the underlying cancer in conjunction with the procedure, especially in cases of metastatic cancer. More

  • GE Healthcare Acquires icometrix, Beckman Coulter Launches First Fully Automated BD-Tau Immunoassay Test, More

    Sep 25 | Diagnostics World | GE HealthCare enters an agreement to acquire icometrix; Beckman Coulter Diagnostics launches the industry's first fully automated brain-derived Tau (BD-Tau) research use only (RUO) immunoassay test; and more. More

  • Follow the Money: Blood-Based Ovarian Cancer Test, Esophageal Diagnostic Platform, More

    Sep 24 | Diagnostics World | Mercy BioAnalytics will commercialize their blood-based ovarian cancer test portfolio; Cyted Health will accelerate the commercial expansion of their diagnostics platform in the U.S.; and more. More

  • Apple Watch Receives FDA Clearance for Hypertension Notifications

    Sep 18 | Diagnostics World | Last week Apple introduced Apple Watch Series 11, offering the most comprehensive set of health features yet, longer battery life, an even more durable cover glass, and 5G cellular capabilities, all in its thinnest and most comfortable design. Among the new features, Apple Watch Series 11 introduced FDA-cleared hypertension notifications, which can alert users if signs of chronic high blood pressure — or hypertension — are detected. More

  • Biomarker Combo Could Guide Treatment of Recurring Ovarian Cancer

    Sep 17 | Diagnostics World | Ovarian cancer relapse is a remarkably diverse and dynamic immunological event that when mapped in conjunction with the genomic characteristic of tumors can provide actionable insights about how to enhance the effectiveness of chemotherapy in extending remission and prolonging survival. That’s the promising possibility suggested by researchers in the field who have newly defined four immunologic subtypes of recurrent ovarian cancers. More
View more articles

 
DXX-Industry-spotlight

merck


Custom Diagnostic Antibody Development & Manufacturing Services

Overcome Process Challenges by outsourcing your custom antibody production to us. How partnering with an antibody production expert can improve your assay, accelerate launch, and maintain your manufacturing.

Learn more